| Behavioural change models for infectious disease transmission: a systematic review (2010–2015) F Verelst, L Willem, P Beutels Journal of The Royal Society Interface 13 (125), 20160820, 2016 | 395 | 2016 |
| Indications for healthcare surge capacity in European countries facing an exponential increase in coronavirus disease (COVID-19) cases, March 2020 F Verelst, E Kuylen, P Beutels Eurosurveillance 25 (13), 2000323, 2020 | 225 | 2020 |
| Lessons from a decade of individual-based models for infectious disease transmission: a systematic review (2006-2015) L Willem, F Verelst, J Bilcke, N Hens, P Beutels BMC Infectious Diseases 17 (1), 612, 2017 | 184 | 2017 |
| Individual decisions to vaccinate one's child or oneself: A discrete choice experiment rejecting free-riding motives F Verelst, L Willem, R Kessels, P Beutels Social Science & Medicine 207, 106-116, 2018 | 69 | 2018 |
| SOCRATES-CoMix: a platform for timely and open-source contact mixing data during and in between COVID-19 surges and interventions in over 20 European countries F Verelst, L Hermans, S Vercruysse, A Gimma, P Coletti, JA Backer, ... BMC medicine 19, 1-7, 2021 | 50 | 2021 |
| Individual factors influencing COVID-19 vaccine acceptance in between and during pandemic waves (July–December 2020) S Valckx, J Crèvecoeur, F Verelst, M Vranckx, G Hendrickx, N Hens, ... Vaccine 40 (1), 151-161, 2022 | 45 | 2022 |
| Drivers of vaccine decision-making in South Africa: A discrete choice experiment F Verelst, R Kessels, W Delva, P Beutels, L Willem Vaccine 37 (15), 2079-2089, 2019 | 37 | 2019 |
| Preferential differences in vaccination decision-making for oneself or one’s child in The Netherlands: a discrete choice experiment J Hoogink, F Verelst, R Kessels, AJ van Hoek, A Timen, L Willem, ... BMC Public Health 20, 1-14, 2020 | 36 | 2020 |
| The influence of risk perceptions on close contact frequency during the SARS-CoV-2 pandemic J Wambua, L Hermans, P Coletti, F Verelst, L Willem, CI Jarvis, A Gimma, ... Scientific reports 12 (1), 5192, 2022 | 22 | 2022 |
| Workplace influenza vaccination to reduce employee absenteeism: An economic analysis from the employers’ perspective F Verelst, P Beutels, N Hens, L Willem Vaccine 39 (14), 2005-2015, 2021 | 17 | 2021 |
| Economic burden of epilepsy in rural Ituri, Democratic Republic of Congo JNS Fodjo, M Mandro, D Wonya'rossi, Y Inaç, F Ngave, R Lokonda, ... EClinicalMedicine 9, 60-66, 2019 | 16 | 2019 |
| No Such Thing as a Free-Rider? Understanding Drivers of Childhood and Adult Vaccination through a Multicountry Discrete Choice Experiment F Verelst, R Kessels, L Willem, P Beutels Vaccines 9 (3), 264, 2021 | 15 | 2021 |
| Sponsorship bias in base-case values and uncertainty bounds of health economic evaluations? A systematic review of herpes zoster vaccination J Bilcke, F Verelst, P Beutels Medical Decision Making 38 (6), 730-745, 2018 | 14 | 2018 |
| Public health impact of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among older adults in the United States D Molnar, EM La, F Verelst, S Poston, J Graham, LA Van Bellinghen, ... Infectious Diseases and Therapy 13 (4), 827-844, 2024 | 3 | 2024 |
| Determinants of basic childhood vaccination coverage in European and OECD countries V Varbanova, F Verelst, N Hens, P Beutels Human Vaccines & Immunotherapeutics 18 (6), 2123883, 2022 | 3 | 2022 |
| Different forms of superspreading lead to different outcomes: Heterogeneity in infectiousness and contact behavior relevant for the case of SARS-CoV-2 EJ Kuylen, A Torneri, L Willem, PJK Libin, S Abrams, P Coletti, N Franco, ... PLOS Computational Biology 18 (8), e1009980, 2022 | 2 | 2022 |
| EE331 Leveraging Time-Use Data to Estimate Market and Non-Market Productivity Losses Due to Respiratory Syncytial Virus (RSV) Disease Among Adults Aged≥ 60 Years in the United … F Verelst, EM La, J Graham, D Molnar Value in Health 26 (6), S120, 2023 | 1 | 2023 |
| The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged≥ 60 years in Japan: results of a Markov model analysis D Kurai, A Mizukami, V Preckler, F Verelst, D Molnar, T Matsuki, Y Ho, ... Expert Review of Vaccines 23 (1), 303-311, 2024 | | 2024 |
| EPH45 Assessing the Public Health Impact of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine Among Older Adults in the United States (US) D Molnar, EM La, F Verelst, D Curran, S Poston, LA Van Bellinghen, ... Value in Health 26 (6), S172, 2023 | | 2023 |
| Ceci n'est pas un lit. Base capacity healthcare matters in a pandemic P Beutels, F Verelst The Lancet Regional Health-Europe 2, 100033, 2021 | | 2021 |
Philippe BeutelsProfessor at Vaccine & Infectious Disease Institute, University of Antwerp, Belgium在 uantwerpen.be 的电子邮件经过验证
